NCT05180422 2023-10-18A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain MetastasisCriterium, Inc.Phase 1/2 Withdrawn